[Biotherapy in colorectal cancer]

Area of Science:

• Oncology
• Medical Biotechnology

Background:

• Metastatic colorectal cancer (mCRC) treatment requires novel therapeutic strategies.
• Monoclonal antibodies represent a significant advancement in targeted cancer therapy.
• These antibodies target specific tumor antigens, offering a more precise approach than traditional chemotherapy.

Purpose of the Study:

• To evaluate the efficacy of monoclonal antibodies in combination with chemotherapy for mCRC.
• To compare patient survival rates between combination therapy and chemotherapy alone.
• To describe the distinct side effect profiles of these novel biotherapies.

Main Methods:

• Review of treatment strategies involving monoclonal antibodies in mCRC.
• Analysis of patient survival data comparing chemotherapy with chemotherapy plus monoclonal antibodies.
• Characterization of side effects associated with bevacizumab and cetuximab.

Main Results:

• Combination therapy with monoclonal antibodies and chemotherapy increased median survival to 20 months, versus 15 months for chemotherapy alone.
• Bevacizumab targets vascular endothelial growth factor (VEGF), a key mediator of angiogenesis.
• Cetuximab targets the epidermal growth factor (EGF) receptor and is approved for pretreated mCRC patients.

Conclusions:

• Monoclonal antibodies are effective additions to chemotherapy regimens for mCRC.
• Bevacizumab and cetuximab offer improved survival outcomes for patients with metastatic colorectal cancer.
• Understanding the unique side effects, such as vascular effects for bevacizumab and acneiform rash for cetuximab, is crucial for patient management.